Background In a randomized trial with a median follow-up of 18.4 months, 6 months of induction chemotherapy with a three-drug regimen comprising 5-fluorouracil (by continuous infusion)-leucovorin, irinotecan, and oxaliplatin (FOLFOXIRI) demonstrated statistically significant improvements in response rate, radical surgical resection of metastases, progression-free survival, and overall survival compared with 6 months of induction chemotherapy with fluorouracil-leucovorin and irinotecan (FOLFIRI). Methods From November 14, 2001, to April 22, 2005, we enrolled 244 patients with metastatic colorectal cancer. To evaluate if the superiority of FOLFOXIRI is maintained in the long term, we updated the overall and progression-free survival data to include events that occurred up to February 12, 2009, with a median follow-up of 60.6 months. We performed a subgroup and a risk-stratified analysis to examine whether outcomes differed in specific patient subgroups, and we analyzed the results of treatment after progression. Survival curves were estimated by the Kaplan-Meier method. Multivariable Cox regression models were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results FOLFOXIRI demonstrated statistically significant improvements in median progression-free survival (9.8 vs 6.8 months, HR for progression = 0.59, 95% CI = 0.45 to 0.76, P <. 001) and median overall survival (23.4 vs 16.7 months, HR for death = 0.74, 95% CI = 0.56 to 0.96, P =. 026) with a 5-year survival rate of 15% (95% CI = 9% to 23%) vs 8% (95% CI = 4% to 14%). The improvements in progression-free survival and, to a lesser extent, in overall survival were evident even when the analysis excluded patients who received radical resection of metastases. With regard to the risk-stratified analysis, FOLFOXIRI results in longer progression-free survival and overall survival than FOLFIRI in all risk subgroups. Conclusions Six months of induction chemotherapy with FOLFOXIRI is associated with a clinically significant improvement in the long-term outcome compared with FOLFIRI with an absolute benefit in survival at 5 years of 7%. © The Author 2010.

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis / G., Masi; E., Vasile; F., Loupakis; S., Cupini; L., Fornaro; G., Baldi; L., Salvatore; C., Cremolini; I., Stasi; I., Brunetti; Fabbri, MARIA AGNESE; Puglisi, Martina; Trenta, Patrizia; C., Granetto; S., Chiara; L., Fioretto; G., Allegrini; L., Crino; M., Andreuccetti; A., Falcone. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - STAMPA. - 103:1(2011), pp. 21-30. [10.1093/jnci/djq456]

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis

FABBRI, MARIA AGNESE;PUGLISI, MARTINA;TRENTA, PATRIZIA;
2011

Abstract

Background In a randomized trial with a median follow-up of 18.4 months, 6 months of induction chemotherapy with a three-drug regimen comprising 5-fluorouracil (by continuous infusion)-leucovorin, irinotecan, and oxaliplatin (FOLFOXIRI) demonstrated statistically significant improvements in response rate, radical surgical resection of metastases, progression-free survival, and overall survival compared with 6 months of induction chemotherapy with fluorouracil-leucovorin and irinotecan (FOLFIRI). Methods From November 14, 2001, to April 22, 2005, we enrolled 244 patients with metastatic colorectal cancer. To evaluate if the superiority of FOLFOXIRI is maintained in the long term, we updated the overall and progression-free survival data to include events that occurred up to February 12, 2009, with a median follow-up of 60.6 months. We performed a subgroup and a risk-stratified analysis to examine whether outcomes differed in specific patient subgroups, and we analyzed the results of treatment after progression. Survival curves were estimated by the Kaplan-Meier method. Multivariable Cox regression models were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results FOLFOXIRI demonstrated statistically significant improvements in median progression-free survival (9.8 vs 6.8 months, HR for progression = 0.59, 95% CI = 0.45 to 0.76, P <. 001) and median overall survival (23.4 vs 16.7 months, HR for death = 0.74, 95% CI = 0.56 to 0.96, P =. 026) with a 5-year survival rate of 15% (95% CI = 9% to 23%) vs 8% (95% CI = 4% to 14%). The improvements in progression-free survival and, to a lesser extent, in overall survival were evident even when the analysis excluded patients who received radical resection of metastases. With regard to the risk-stratified analysis, FOLFOXIRI results in longer progression-free survival and overall survival than FOLFIRI in all risk subgroups. Conclusions Six months of induction chemotherapy with FOLFOXIRI is associated with a clinically significant improvement in the long-term outcome compared with FOLFIRI with an absolute benefit in survival at 5 years of 7%. © The Author 2010.
1ST-LINE TREATMENT, INFUSIONAL FLUOROURACIL, IMPROVED SURVIVAL, TUMOR RESPONSE, PHASE-III, OXALIPLATIN, IRINOTECAN, BEVACIZUMAB, LEUCOVORIN, FOLFOXIRI
01 Pubblicazione su rivista::01a Articolo in rivista
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis / G., Masi; E., Vasile; F., Loupakis; S., Cupini; L., Fornaro; G., Baldi; L., Salvatore; C., Cremolini; I., Stasi; I., Brunetti; Fabbri, MARIA AGNESE; Puglisi, Martina; Trenta, Patrizia; C., Granetto; S., Chiara; L., Fioretto; G., Allegrini; L., Crino; M., Andreuccetti; A., Falcone. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - STAMPA. - 103:1(2011), pp. 21-30. [10.1093/jnci/djq456]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/542597
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 48
  • Scopus 129
  • ???jsp.display-item.citation.isi??? 132
social impact